Joe Bennett MD

Lymphoma doc at @KUcancercenter #lmsm | Distance Runner | High handicap Golfer

[KU Cancer Center @KUcancercenter]

Good morning #ASCO26! Later today, don’t miss Dr. Marc Hoffmann presenting “Golcadomide (GOLCA), a potential, first‑in‑class, oral CELMoD + Pola‑RCHP in patients with newly diagnosed aggressive B‑cell lymphoma (a‑BCL): Safety and 12‑month efficacy results.” It’s part of the Rapid Oral Abstract session happening in Room E450a at 1pm.

[KU Cancer Center @KUcancercenter]

Congratulations to Jesus Gonzalez Lugo, MD, recipient of the Winn Career Development Award, a national program that supports clinicians leading community‑focused clinical research. Learn more: https://t.co/P0vlvEqGsK

[Joe Bennett MD @JOEBENNETTMD]

Bruton Tyrosine Kinase Inhibition in Combination With Bispecific Antibodies for Richter's Syndrome: A Report of Two Cases and Mini Review. https://t.co/pmtTDM0IlF #Lymsm #CLL #Richters

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

We are thrilled to see @KUcancercenter University of Kansas Cancer Center recognized among the Top 50 Cancer Centers worldwide on the LARVOL scale—a tremendous achievement made possible with the support of @JOEBENNETTMD.
@Larvol @USMIRCNEWS @US_HMC @oncodaily @MedwatchKate

[Joe Bennett MD @JOEBENNETTMD]

@BuffettCancer @lymphomaphilia Congrats!

[Papa Heme @Papa_Heme]

Hematology Fellows

Remember this flow pattern!

APL: Promyelocytes one step more differentiated from myeloblasts and lose CD34 expression. Blasts typically CD34+, but APL CD34-/

CD13+, CD33+, CD117+, MPO+, CD34-, HLADR-

[Joe Bennett MD @JOEBENNETTMD]

Dr. Marc Hoffmann @KUcancercenter presented Golcadomide + Rituximab in R/R NHL. Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results Median 4L prior therapy, many CAR-T exposed / Bispecific exposed, 0.4mg Golca ORR 58% in all patients, ctDNA deep reductions even in high risk TP53mut disease. Promising data! #ASH25 #lymsm

[Joe Bennett MD @JOEBENNETTMD]

@DrJasonWestin presented R-CHOP + Golcadomide. High rates of MRD negativity by ctDNA, safety data is encouraging. Phase 3 GOLSEEK-1 is pending. #lymsm

[Joe Bennett MD @JOEBENNETTMD]

Final analysis of ROSEWOOD 3L setting Zanubrutinib + Obinutuzumab (Z+O). ORR 70%, CR 42%, TTNT 51mo. mOS not reached. TRAE 9.8% stopped from AEs. Obinutuzumab definitely active with prior Rituximab in cFL. Patient selection is key, several good options cFL. #ASH2025 #lymsm

[Joe Bennett MD @JOEBENNETTMD]

@Abdallah81MD @KUcancercenter @AlmaHabibMD @USMIRCNEWS @OncoAlert Welcome @AlmaHabibMD !!! 🎉🎈🎊

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

⏳2 days left for the 1st National ICE-T meeting #mmsm #USMIRC @OncoAlert @oncodaily @NausheenAhmedMD @HemSandoval @mshahzadmd @mumairmushtaq @kczmj @anup_kasi @AtrashShebli @medicalwatchBC @Larvol

https://t.co/1WVSeo7wDt

[Blood Advances @BloodAdvances]

Zanubrutinib demonstrated reduced risk of progression/death compared to ibrutinib, acalabrutinib, and bendamustine or idelalisib+rituximab. https://t.co/ojHOlqWzT3 #lymphoidneoplasia

[Joe Bennett MD @JOEBENNETTMD]

@ShetalLife77 I’ll be full time, malignant hematology, specializing in lymphoma at U Kansas 🤓🤓🤓

[Joe Bennett MD @JOEBENNETTMD]

Goodbye fellow cubicle, we anxiously await the attending office. Many hours spent here: charting, editing papers, studying, spinning the proverbial hamster wheel. Ready for the next phase of my career!

[KU Cancer Center @KUcancercenter]

We’re in Briarcliff! Now patients have 3 locations to choose from in the Northland. Ranked in the top 1% nationwide, #KUCancerCenter offers unrivaled expertise and experience in diagnosing and treating all forms of cancer. Learn more: https://t.co/3XRkNTtDqY

[Joe Bennett MD @JOEBENNETTMD]

Structured Exercise after Adjuvant Chemo for Colon Cancer ⁦@KUHemOncFellow⁩ with Dr. Sunny Cai and Dr. ⁦@lihaoran⁩ . Good for all cancer patients to exercise post-chemo, but especially CRC! 🏃🏊 #MedTwitter #ColonCancer #ExerciseIsmedicine https://t.co/RlY5G47Wou

[Joe Bennett MD @JOEBENNETTMD]

@KUHemOncFellow journal club today with Drs. @lihaoran and Sunny Cai. 🏃‍♂️💪 Colon cancer survivors

Structured aerobic + resistance training after chemo cut recurrence risk:
➡️ DFS HR = 0.72 , p=0.02
28% risk reduction!
https://t.co/SPDpXYbQkp

#OncoFit #ColorectalCancer #NEJM #MedTwitter #ExerciseIsMedicine

[Ajay Major, MD, MBA @majorajay]

Prophy dex with glofitamab (4 mg after 1st glofi & bid for 3 days after C1D8, C1D15, C2D1) with reduction in CRS from 63% in trial to 32%, all G1-2. Moving towards outpatient glofi. #18ICML #lymsm

[Joe Bennett MD @JOEBENNETTMD]

Excited to dive into this one for some casual reading. It’s a small book so should be quick read. I’ll post my thoughts once finished :) #MedTwitter #Hematology